Key Points
- Director Robert Gould sold 15,000 shares on Jan. 2 at an average price of $11.87 for a total of $178,050, reducing his holdings to 469,864 shares (a 3.09% ownership decrease) per the SEC filing.
- Shares opened at $9.99 with a 50‑day/200‑day SMA of $10.63/$8.71, a market cap of $540.66M and a negative PE; analysts' average rating is Hold with a consensus price target of $19, though several firms recently raised targets (e.g., Piper Sandler $23, HC Wainwright $25).
- About 89.83% of the stock is owned by hedge funds and other institutional investors, and Fulcrum is a clinical‑stage biopharma advancing epigenetic therapies, notably FTX‑6058 for sickle cell disease and beta‑thalassemia.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Robert Gould sold 15,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the sale, the director owned 469,864 shares of the company's stock, valued at approximately $5,577,285.68. This represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Fulcrum Therapeutics Stock Performance
Shares of Fulcrum Therapeutics stock opened at $9.99 on Wednesday. The company has a 50-day simple moving average of $10.63 and a two-hundred day simple moving average of $8.71. The stock has a market capitalization of $540.66 million, a PE ratio of -8.47 and a beta of 3.20. Fulcrum Therapeutics, Inc. has a 52-week low of $2.32 and a 52-week high of $15.74.
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). As a group, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently weighed in on FULC shares. Royal Bank Of Canada boosted their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a "sector perform" rating in a research note on Monday, December 8th. Piper Sandler reiterated an "overweight" rating and issued a $23.00 price objective (up from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. HC Wainwright upped their target price on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, December 8th. Truist Financial raised their price target on shares of Fulcrum Therapeutics from $14.00 to $18.00 and gave the company a "buy" rating in a report on Thursday, December 11th. Finally, Leerink Partners set a $20.00 price objective on shares of Fulcrum Therapeutics and gave the company an "outperform" rating in a report on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $19.00.
Get Our Latest Stock Report on Fulcrum Therapeutics
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of FULC. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Fulcrum Therapeutics by 53.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company's stock worth $31,572,000 after buying an additional 1,589,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Fulcrum Therapeutics in the second quarter worth approximately $9,207,000. Exome Asset Management LLC boosted its stake in shares of Fulcrum Therapeutics by 143.0% during the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock worth $1,985,000 after acquiring an additional 405,538 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Fulcrum Therapeutics by 448.4% during the 2nd quarter. Invesco Ltd. now owns 470,333 shares of the company's stock worth $3,236,000 after acquiring an additional 384,566 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its position in shares of Fulcrum Therapeutics by 8.9% during the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company's stock valued at $42,971,000 after acquiring an additional 382,485 shares during the period. 89.83% of the stock is owned by hedge funds and other institutional investors.
About Fulcrum Therapeutics
(
Get Free Report)
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
